In Kenya, a country with one of the largest HIV treatment programs in Africa, viral load monitoring has become a routine success story. Clinics across the country now regularly measure patients' viral loads, helping to track treatment effectiveness and identify when drug resistance may be emerging. Yet a critical gap persists: many patients who test positive for HIV do not start antiretroviral therapy (ART) on the same day, as World Health Organization (WHO) guidelines recommend. Instead, they wait days or even weeks, a delay that can increase the risk of disease progression and onward transmission. This article examines why same-day ART initiation lags behind in Kenya's public facilities, how private clinics differ, and what steps might close the gap.

Viral Load Monitoring Works, but Treatment Starts Late

Kenya's HIV clinics, supported by major donors such as PEPFAR and the Global Fund, have invested heavily in viral load testing. As of late 2024, the country reported that roughly 85% of people on ART had received a viral load test in the previous 12 months, meeting international targets. These tests help clinicians confirm that treatment is suppressing the virus, and they are a cornerstone of quality care. However, the same urgency does not apply to the start of therapy. WHO guidelines have recommended same-day ART initiation since 2015, following evidence that early treatment reduces mortality and transmission. Kenya adopted these guidelines in 2016, but implementation remains uneven. At many public clinics in urban and rural areas, patients who test positive are asked to return for a second visit to begin ART, often a week or more later. During that wait, some patients never come back. A 2023 cohort study in western Kenya found that nearly 30% of patients eligible for same-day initiation were not started on ART at their first visit. The reasons vary: clinicians may want to complete additional lab tests, counsel patients about adherence, or address fears about side effects. Yet the result is the same: a missed opportunity to suppress the virus quickly. As Dr. Grace Mwangi, a clinical officer at the Mbagathi District Hospital HIV clinic in Nairobi, told me, 'We are good at monitoring, but we are slow to start. It is a system problem, not a lack of will.' The gap between monitoring and initiation is not unique to Kenya; a similar pattern has been documented in other sub-Saharan African countries, where viral load coverage has expanded rapidly but same-day ART rates have stagnated. In Kenya, the contrast is stark: clinics that consistently achieve viral load testing targets often have same-day initiation rates below 50%. This disconnect suggests that the metrics donors reward—such as viral load coverage—may not align with the clinical goal of rapid treatment start. The consequence is that patients who are ready for therapy face unnecessary delays, and the health system misses a chance to improve outcomes at a critical moment.

Why Same-Day ART Remains Elusive in Public Facilities

Overcrowded clinics are a primary barrier. Many public HIV clinics in Kenya see 50 to 100 patients per day, with long queues and limited staff. Nurses and clinical officers are stretched thin, and initiating ART requires time for counseling, adherence preparation, and documentation. In such settings, same-day initiation can be logistically challenging. A 2022 study published in the Journal of the International AIDS Society found that staff shortages were the strongest predictor of delayed ART initiation in Kenyan public facilities. Clinics with fewer than two nurses per shift had same-day initiation rates roughly half those of better-staffed clinics.

Lab turnaround times for CD4 counts and other baseline tests can exceed 48 hours, even when point-of-care machines are available. Although WHO guidelines no longer require a CD4 count before starting ART, many Kenyan clinicians still wait for results, citing caution and a desire to document baseline immune status. This practice, while clinically understandable, introduces an average delay of three to five days. In some facilities, samples are sent to centralized labs, adding transport time. As a result, patients are told to return once results are ready, a process that can stretch to two weeks in remote areas. This lab-related delay is a recurring theme: in many public clinics, the lack of point-of-care CD4 machines means that even the most motivated clinician cannot start ART on the same day because the results are not available. The same barrier also affects other baseline tests, such as creatinine levels, which are sometimes required before prescribing certain antiretroviral regimens.

Another factor is the practice of sending patients home to 'prepare' for lifelong therapy. Clinicians may encourage patients to discuss their status with family members, arrange for transport to future appointments, or secure a food supply to take with medications. While these considerations are valid, they can become a rationale for indefinite postponement. Some clinicians also express concern about the risk of immune reconstitution inflammatory syndrome (IRIS) in patients with very low CD4 counts, though studies show that same-day ART does not increase IRIS risk when patients are monitored properly. Fear of side effects—real or perceived—can also lead providers to delay initiation until a follow-up visit.

Financial incentives play a role as well. Public clinics are often funded based on the number of patients enrolled in care and the volume of viral load tests performed, rather than on the timeliness of ART initiation. There is no penalty for delaying a start by a week, and no bonus for same-day initiation. This misalignment means that the system does not actively encourage rapid treatment. In contrast, viral load testing is a reimbursable service under many donor contracts, creating a de facto incentive to prioritize monitoring over speed of initiation.

Private Sector Shows a Different Pattern

Private clinics in Nairobi and other urban centers offer a contrasting picture. At facilities such as the Nairobi West Hospital HIV Clinic and private practices in Karen, same-day ART initiation is routine. Patients who test positive are started on therapy within hours, often in a single visit that includes counseling, baseline labs, and a first dose. These clinics typically have shorter waiting times, dedicated counseling rooms, and staff trained specifically in rapid initiation. They also have access to point-of-care CD4 machines that return results in 20 minutes, eliminating the need for a return visit.

The private sector's approach is driven partly by market competition. Patients who pay out-of-pocket—or have private insurance—expect convenience and efficiency. A delay of several days might drive them to another clinic. However, the cost is a barrier: a single private ART initiation visit, including labs and the first month of drugs, can cost roughly US$30 to $60, beyond the reach of many Kenyans. As a result, private clinics serve a wealthier urban population, and their model is not easily replicated in public facilities. Yet the contrast highlights what is possible when resources and incentives align.

Loss-to-follow-up rates are lower in private settings. A study by Odhiambo et al. (2021) published in the journal AIDS Care compared public and private HIV clinics in Nairobi and found that 12-month retention on ART was 85% in private clinics versus 65% in public facilities. Same-day initiation likely contributes to this difference: when patients start therapy immediately, they are more engaged and less likely to drop out before their first refill. Private clinics also offer more flexible appointment times and telephone reminders, which help maintain adherence. However, the wealth gradient is stark: patients in private clinics are more likely to have stable housing, food security, and supportive family networks, all of which facilitate adherence regardless of initiation speed.

Evidence Base: What Trials Show About Early Start

The scientific case for same-day ART initiation is strong. The landmark START trial, published in 2015, showed that starting ART at a CD4 count above 500 cells per microliter reduced the risk of serious illness or death by 57% compared with deferring treatment until the CD4 count fell below 350. This finding, along with evidence from observational studies, led the WHO to adopt a 'treat all' policy in 2015, recommending that everyone with HIV start ART as soon as possible after diagnosis. Subsequent trials, including the TEMPRANO trial in Côte d'Ivoire, confirmed the benefits of early initiation, including lower rates of tuberculosis and other infections.

Kenya formally adopted the 'treat all' approach in 2016, but implementation has been incomplete. A 2021 study from the Kenya Medical Research Institute (KEMRI) found that only 38% of newly diagnosed patients in public clinics started ART on the same day, despite national guidelines. The study also showed that delayed initiation was associated with higher rates of viral rebound at 12 months, even among patients who eventually achieved viral suppression. This suggests that the early days of therapy are critical for establishing adherence patterns. When patients start quickly, they are more likely to adhere consistently from the outset.

Kenyan cohort data confirm the gap. An analysis of electronic medical records from 30 public clinics in three counties found that the median time from diagnosis to ART initiation was 14 days in 2022, down from 21 days in 2018 but still far from the same-day target. The same analysis showed that patients who started ART within 7 days had a 20% lower risk of loss to follow-up at 6 months compared with those who started after 14 days. These data, while observational, reinforce the message that speed matters. The evidence base is clear, but translating it into routine practice requires addressing the operational barriers that slow initiation.

Operational Barriers Beyond the Clinic Walls

Transport costs are a significant obstacle. Many patients in rural areas live far from the nearest clinic, and returning for a second visit to start ART can mean a full day of lost wages and bus fare. A study in Homa Bay County found that the average round-trip cost to a clinic was roughly US$3 to $5, a non-trivial sum for households living on less than $2 per day. For patients who are diagnosed at a mobile testing event or a community outreach site, the challenge is even greater: they may be referred to a clinic that is far from home, and the logistics of getting there can be daunting. Same-day initiation would eliminate one trip, reducing the financial burden.

Stigma remains a powerful deterrent. Patients who test positive may not want to disclose their status to family members immediately, and starting ART requires taking daily medication that could reveal their status. Some patients prefer to delay initiation until they have had time to process the diagnosis and decide whom to tell. Clinicians sometimes accommodate this by scheduling a follow-up visit for ART initiation, giving patients a chance to 'prepare.' However, this approach can backfire if the patient's fear grows or if they are discouraged by a partner or family member. Male partners, in particular, have been shown to block women from starting ART quickly, sometimes due to stigma or misconceptions about the drugs.

Food insecurity is another barrier. Antiretroviral drugs can cause gastrointestinal side effects, especially in the first weeks, and taking them on an empty stomach can worsen nausea. Clinicians may hesitate to start ART if a patient reports not having enough food, fearing that side effects will lead to discontinuation. While this concern is legitimate, it can lead to indefinite delays. Some clinics have started providing food vouchers or nutritional counseling as part of same-day initiation, but these programs are not widespread. Without food support, the gap between guidelines and practice is likely to persist.

Donor and Government Priorities Shape the Gap

The funding landscape for HIV in Kenya is dominated by PEPFAR and the Global Fund, which together provide roughly 70% of the country's HIV budget. These donors have invested heavily in viral load machines, laboratory infrastructure, and monitoring systems. Kenya now has one of the highest densities of viral load testing platforms in sub-Saharan Africa. However, less funding has been directed toward the operational changes needed to support same-day initiation, such as hiring additional nurses, installing point-of-care CD4 machines in every clinic, or training staff in rapid initiation protocols. The result is a system that is good at measuring outcomes but slower at delivering timely care.

Kenya's domestic health budget is constrained by high levels of public debt, which limits the government's ability to fill gaps left by donors. The national HIV program has prioritized scaling up viral load testing to meet 95-95-95 targets, and these efforts have been successful. But the same metrics do not capture the timeliness of initiation. As Dr. James Nyikal, a health economist at the University of Nairobi, noted, 'What gets measured gets done. We measure viral load, so viral load improves. We do not measure days to initiation, so that stagnates.' Aligning donor performance indicators with clinical guidelines could shift incentives, but it would require renegotiating contracts and reallocating funds.

The upcoming selection of a new executive director for the Global Fund, as reported in The Lancet in June 2026, could be an opportunity to reassess priorities. The Global Fund's next leader will face pressure to balance investments in monitoring with support for service delivery improvements. In Kenya, advocates argue that a modest reallocation of funds from laboratory infrastructure to human resources and point-of-care devices could dramatically improve same-day initiation rates. However, such changes are politically sensitive, as they would require reducing support for well-established programs. The status quo, while imperfect, is stable.

Bridging the Gap: Practical Steps for Clinics

Several strategies have shown promise in closing the gap between guidelines and practice. Task-shifting—allowing nurses and clinical officers to initiate ART without requiring a doctor's approval—has been adopted in many Kenyan clinics and is associated with higher rates of same-day initiation. A study by Ochieng et al. (2020) published in the Journal of the International AIDS Society found that clinics in Kisumu County with nurse-led initiation had same-day rates of 65%, compared with 40% in doctor-led clinics. Expanding this approach to all public facilities would require training and regulatory changes, but the evidence supports it.

Point-of-care CD4 machines, which provide results in 20 minutes, can eliminate the lab delay that forces patients to return. Several manufacturers produce portable devices that are suitable for rural clinics. The cost, roughly US$5,000 per machine plus per-test consumables, is a barrier, but bulk procurement by donors could reduce prices. Some pilot programs in Kenya have shown that equipping clinics with these machines, combined with same-day initiation protocols, can increase initiation rates to over 80%.

Peer counselors—people living with HIV who have successfully navigated treatment—can address fear and stigma. When a newly diagnosed patient meets a peer who shares their experience and can answer questions about side effects, adherence, and disclosure, they are more likely to start therapy immediately. Programs in Uganda and South Africa have demonstrated that peer support at the point of diagnosis increases same-day initiation by 20–30%. Kenya's national HIV program has begun integrating peer counselors into clinics, but coverage remains patchy.

Finally, national quality improvement programs that set targets for same-day initiation and provide feedback to clinics can drive change. Tanzania's 'Jitambue' program, described in a 2023 report by the Tanzania Ministry of Health and supported by PEPFAR, reduced the median time to ART initiation from 30 days to 7 days over two years. Kenya could adopt a comparable approach, using existing data systems to track initiation timeliness and reward clinics that improve. Such a program would require political will and modest investment, but it would align the system with the evidence. However, even with these interventions, challenges remain. Staff turnover, supply chain interruptions for point-of-care devices, and persistent stigma may limit the impact of any single strategy. Closing the gap between guidelines and practice will require sustained effort across multiple fronts, and full same-day initiation may remain an aspirational target for years to come.

This article is for informational purposes only and does not constitute medical advice. Individuals seeking HIV testing or treatment should consult a healthcare provider. The views expressed are those of the author and do not necessarily reflect those of any organization.